Arcturus Therapeutics Holdings Inc. (ARCT)

Market Cap	568.43M
Revenue (ttm)	163.87M
Net Income (ttm)	-71.96M
Shares Out	27.04M
EPS (ttm)	-2.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	291,995
Open	21.23
Previous Close	20.55
Day's Range	20.94 - 21.70
52-Week Range	17.52 - 45.00
Beta	2.61
Analysts	Strong Buy
Price Target	65.00 (+209.23%)
Earnings Date	Nov 12, 2024

About ARCT

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 180
• Stock Exchange: NASDAQ
• Ticker Symbol: ARCT
• Website: https://arcturusrx.com

Analyst Forecast

According to 7 analysts, the average rating for ARCT stock is "Strong Buy." The 12-month stock price forecast is $65.0, which is an increase of 209.23% from the latest price.

Price Target

$65.0

(209.23% upside)

Analyst Consensus: Strong Buy